Spectral AI (MDAI) 주식 개요
인공지능(AI) 회사인 Spectral AI는 미국에서 예측 의료 진단에 주력하는 기업입니다. 자세히 보기
MDAI Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$5
FV
63.6% 저평가 내재 할인율516
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Spectral AI, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$1.82 |
| 52주 최고가 | US$3.21 |
| 52주 최저가 | US$1.18 |
| 베타 | 1.15 |
| 1개월 변동 | -31.06% |
| 3개월 변동 | 18.18% |
| 1년 변동 | -16.90% |
| 3년 변동 | -82.58% |
| 5년 변동 | -81.24% |
| IPO 이후 변동 | -81.24% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 17
MDAI: FDA Burn Care Clearance Will Drive Future Commercialization Potential
Spectral AI's analyst price target has moved from $3 to $4, with analysts highlighting the recent FDA clearance of the DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key factor in their updated view. What’s in the News for Spectral AI The U.S. FDA has granted De Novo Classification for Spectral AI’s DeepView System, authorizing commercial distribution for burn care use in burn centers, trauma centers, and emergency departments.
내러티브 업데이트 • Jun 03
MDAI: FDA Clearance And BARDA Funding Will Support Future Burn Preparedness
Spectral AI's analyst price target has increased by $1 to $4, with analysts citing the recent FDA clearance of its DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key driver of the reassessment. What's in the News U.S. FDA granted De Novo Classification for Spectral AI's DeepView System, authorizing commercial distribution for burn care in burn centers, trauma centers, and emergency departments.
내러티브 업데이트 • May 24
Spectral AI (MDAI): DeepView AI Automated Wound Imaging System Granted FDA Approval!!!
Well this is the news I and many others have been waiting ten months for, and certainly in my case expecting given the information in the public domain… the first of its kind automated wound imaging and assessment device has been granted US FDA approval!!! Years of work by the dedicated team at Spectral AI and partners such as the US Government’s BARDA have put this relatively small company on the map, with a device that offers burn specialists and clinicians the opportunity to potentially improve patient outcomes and hopefully save time and money for all concerned.Recent updates
내러티브 업데이트 • Jun 17
MDAI: FDA Burn Care Clearance Will Drive Future Commercialization Potential
Spectral AI's analyst price target has moved from $3 to $4, with analysts highlighting the recent FDA clearance of the DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key factor in their updated view. What’s in the News for Spectral AI The U.S. FDA has granted De Novo Classification for Spectral AI’s DeepView System, authorizing commercial distribution for burn care use in burn centers, trauma centers, and emergency departments.내러티브 업데이트 • Jun 03
MDAI: FDA Clearance And BARDA Funding Will Support Future Burn Preparedness
Spectral AI's analyst price target has increased by $1 to $4, with analysts citing the recent FDA clearance of its DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key driver of the reassessment. What's in the News U.S. FDA granted De Novo Classification for Spectral AI's DeepView System, authorizing commercial distribution for burn care in burn centers, trauma centers, and emergency departments.내러티브 업데이트 • May 24
Spectral AI (MDAI): DeepView AI Automated Wound Imaging System Granted FDA Approval!!!
Well this is the news I and many others have been waiting ten months for, and certainly in my case expecting given the information in the public domain… the first of its kind automated wound imaging and assessment device has been granted US FDA approval!!! Years of work by the dedicated team at Spectral AI and partners such as the US Government’s BARDA have put this relatively small company on the map, with a device that offers burn specialists and clinicians the opportunity to potentially improve patient outcomes and hopefully save time and money for all concerned.분석 기사 • May 15
Analyst Estimates: Here's What Brokers Think Of Spectral AI, Inc. (NASDAQ:MDAI) After Its First-Quarter Report
The analysts might have been a bit too bullish on Spectral AI, Inc. ( NASDAQ:MDAI ), given that the company fell short...내러티브 업데이트 • May 08
MDAI: BARDA Funding And New Leadership Will Support Future Burn Preparedness
Analysts have trimmed their price target on Spectral AI to $6.00, reflecting slightly lower profit margin assumptions and a higher forward P/E multiple, even though their fair value estimate remains at $6.00 and discount rate expectations have eased. What's in the News Spectral AI received $31.7 million in immediate, non dilutive funding from the Biomedical Advanced Research and Development Authority to support additional feature development for its DeepView System, alongside a commitment from the company to contribute $9.7 million to total development costs (BARDA contract 75A50123C00049).내러티브 업데이트 • Apr 21
MDAI: BARDA Funding And New Leadership Will Support Future Commercialization Potential
Analysts have updated their price targets on Spectral AI to reflect revised assumptions for discount rates, revenue growth, profit margins, and a higher forward P/E. These changes have resulted in a revised assessment of the potential upside in the shares.내러티브 업데이트 • Apr 06
MDAI: BARDA Funding And Leadership Transition Will Support Future Burn Preparedness
Analysts have nudged their Spectral AI price target to $6.00, citing small adjustments to assumptions on discount rate, revenue trends, profit margins, and a very high future P/E multiple as key drivers of the updated view. What's in the News Spectral AI received $31.7 million in immediate, non dilutive funding from the Biomedical Advanced Research and Development Authority to support additional feature development for its DeepView System, an AI driven burn wound imaging technology, alongside a company commitment of $9.7 million to total development costs (BARDA contract 75A50123C00049).분석 기사 • Mar 27
News Flash: Analysts Just Made A Stunning Upgrade To Their Spectral AI, Inc. (NASDAQ:MDAI) Forecasts
Shareholders in Spectral AI, Inc. ( NASDAQ:MDAI ) may be thrilled to learn that the analysts have just delivered a...내러티브 업데이트 • Mar 23
MDAI: BARDA Funding Will Support Future Burn Preparedness Commercialization Potential
Analysts have trimmed their price target on Spectral AI from $7.45 to $6.00 as they now apply a higher discount rate, expect a 28.16% decline in revenue growth, see profit margins at 12.86%, and use a much higher forward P/E multiple of 254.14x in their models. What's in the News Spectral AI received $31.7 million in immediate, non-dilutive funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to accelerate additional features for its DeepView System, with the company committing a further $9.7 million of its own capital to the project (Key Developments).내러티브 업데이트 • Mar 09
MDAI: New CEO Appointment Will Support Future Margin Recovery Potential
Analysts have trimmed their Spectral AI price target to $3.00, citing slightly higher discount rates, softer revenue growth expectations, a lower projected profit margin, and a higher assumed future P/E multiple in their updated model. What's in the News Spectral AI appointed Vincent S.내러티브 업데이트 • Feb 23
MDAI: Leadership Transition And Commercialization Progress Will Support Future Margin Recovery
Narrative Update on Spectral AI Analysts have kept their Spectral AI price target steady at $3.00, with unchanged fair value assumptions and only small tweaks to the discount rate, revenue growth, profit margin, and future P/E inputs. These adjustments support a largely unchanged outlook.새로운 내러티브 • Feb 14
Spectral AI: First of Its Kind Automated Wound Healing Prediction
Overview Spectral AI is an artificial intelligence business offering predictive wound diagnostics designed to facilitate faster and more accurate treatment decisions in wound care. Spectral’s shares are traded as NASDAQ: MDAI.내러티브 업데이트 • Feb 07
MDAI: Contract Timing Shift Will Support Future Margin Recovery And Revenue Upside
Analysts have adjusted their price target on Spectral AI to reflect a slightly lower discount rate, a small change in expected revenue contraction, and an updated future P/E of about 86x, while keeping fair value steady at US$3.00. What's in the News Spectral AI revised its earnings guidance for fiscal year 2025, reducing expected revenue guidance from US$21.5 million to US$18.5 million.분석 기사 • Jan 27
Spectral AI, Inc. (NASDAQ:MDAI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...내러티브 업데이트 • Jan 23
MDAI: Contract Timing Shift Will Support Future Margin And Revenue Upside
Analysts now estimate Spectral AI's fair value at US$3.00 per share, unchanged from the prior US$3.00 view, as minor adjustments to the discount rate, revenue outlook, profit margin and future P/E assumptions leave their overall price target the same. What's in the News Spectral AI revised its revenue guidance for fiscal 2025 to US$18.5 million from US$21.5 million, reflecting updated expectations for the year (company guidance).내러티브 업데이트 • Jan 08
MDAI: Future Contract Timing Shift Will Support Stronger Profit Margins
Analysts have trimmed their price targets on Spectral AI to US$3.00, pointing to updated assumptions that include a slightly higher discount rate, a smaller revenue decline, a higher profit margin outlook, and a lower future P/E multiple of about 88x. What's in the News Spectral AI reduced its revenue guidance for fiscal 2025 from US$21.5 million to US$18.5 million, citing timing of work on its BARDA contract and effects from the current US government shutdown (Key Developments).내러티브 업데이트 • Dec 14
MDAI Future Revenue Shift From Contracts Will Support Stronger Profit Margins
Analysts have trimmed their price target on Spectral AI to reflect a modestly lower fair value estimate of 3.0 dollars from 3.5 dollars. They cited slightly higher perceived risk, even as outlooks improve for revenue contraction and profit margins, along with a marginally more attractive future earnings multiple.분석 기사 • Nov 28
Spectral AI, Inc. (NASDAQ:MDAI) Shares Could Be 26% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Spectral AI fair value estimate is US$2.14 Current share price...분석 기사 • Nov 28
The Market Doesn't Like What It Sees From Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Yet As Shares Tumble 27%
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • Oct 23
At US$2.24, Is Spectral AI, Inc. (NASDAQ:MDAI) Worth Looking At Closely?
Spectral AI, Inc. ( NASDAQ:MDAI ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively...분석 기사 • Sep 06
Market Cool On Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Pushing Shares 25% Lower
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • Aug 16
Spectral AI, Inc. (NASDAQ:MDAI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.09
NasdaqCM:MDAI 1 Year Share Price vs Fair Value Explore Spectral AI's Fair Values from the Community and select yours...분석 기사 • Jul 29
Estimating The Intrinsic Value Of Spectral AI, Inc. (NASDAQ:MDAI)
Key Insights The projected fair value for Spectral AI is US$2.91 based on 2 Stage Free Cash Flow to Equity Spectral...분석 기사 • Jun 22
The Market Lifts Spectral AI, Inc. (NASDAQ:MDAI) Shares 50% But It Can Do More
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders have had their patience rewarded with a 50% share price jump in the last...분석 기사 • Jun 22
The Market Lifts Spectral AI, Inc. (NASDAQ:MDAI) Shares 50% But It Can Do More
The Spectral AI, Inc. ( NASDAQ:MDAI ) share price has done very well over the last month, posting an excellent gain of...
새로운 내러티브 • May 06
FDA Submission Success Will Advance DeepView Global Opportunities
Successful burn validation study and international expansion strengthen FDA submission, potentially accelerating approval and driving future revenue growth.분석 기사 • Mar 08
Take Care Before Jumping Onto Spectral AI, Inc. (NASDAQ:MDAI) Even Though It's 28% Cheaper
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders that were waiting for something to happen have been dealt a blow with a...분석 기사 • Feb 10
Estimating The Intrinsic Value Of Spectral AI, Inc. (NASDAQ:MDAI)
Key Insights Spectral AI's estimated fair value is US$2.15 based on 2 Stage Free Cash Flow to Equity With US$2.06 share...분석 기사 • Dec 18
Investors Still Aren't Entirely Convinced By Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Despite 39% Price Jump
Despite an already strong run, Spectral AI, Inc. ( NASDAQ:MDAI ) shares have been powering on, with a gain of 39% in...주주 수익률
| MDAI | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 0% | -1.1% | 1.4% |
| 1Y | -16.9% | -20.7% | 25.7% |
수익률 대 산업: MDAI은 지난 1년 동안 -20.7%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: MDAI은 지난 1년 동안 25.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| MDAI volatility | |
|---|---|
| MDAI Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: MDAI의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: MDAI의 주간 변동성(11%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| n/a | 65 | Vince Capone | www.spectral-ai.com |
인공지능(AI) 회사인 Spectral AI는 미국에서 예측 의료 진단에 주력하는 회사입니다. 이 회사는 독점적인 AI 알고리즘을 사용하여 상처가 나타난 초기 시점에서 육안으로는 보이지 않는 인체 조직의 특성을 완전히 손상된 조직, 부분적으로 손상된 조직, 건강한 조직으로 구분하고 향후 특정 시점까지 상처가 치유될 수 있는지에 대한 이진 예측을 제공하여 의사가 환자의 상처 치료에 대해 보다 정확하고 시기 적절하며 정보에 입각한 결정을 내릴 수 있도록 지원하는 딥뷰 시스템(DeepView System)을 제공합니다. 이 시스템은 또한 손상된 조직 이미지를 캡처하는 독점적인 다중 스펙트럼 광학 및 센서로 구성된 AI-Burn 소프트웨어와 MSI 이미징 기술을 개발합니다.
Spectral AI, Inc. 기초 지표 요약
| MDAI 기초 통계 | |
|---|---|
| 시가총액 | US$57.92m |
| 순이익 (TTM) | -US$13.88m |
| 매출 (TTM) | US$16.93m |
3.4x
주가매출비율(P/S)-4.2x
주가수익비율(P/E)MDAI는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| MDAI 손익계산서 (TTM) | |
|---|---|
| 매출 | US$16.93m |
| 매출원가 | US$9.15m |
| 총이익 | US$7.78m |
| 기타 비용 | US$21.66m |
| 순이익 | -US$13.88m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.44 |
| 총이익률 | 45.97% |
| 순이익률 | -81.97% |
| 부채/자본 비율 | -95.5% |
MDAI의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/20 21:13 |
| 종가 | 2026/06/18 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Spectral AI, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Michael Gorman | BTIG |
| Carl Byrnes | Northland Capital Markets |
| Vadim Alexandre Khalil | SP Angel Corporate Finance LLP |